Skip to main content

  • 4-Year PRAGUE-17 Follow-Up: Continued Non-Inferior Risk Prevention from LAA Closure vs. NOAC in High-Risk AF

    Left atrial appendage closure (LAAC) remains non-inferior to non-vitamin K oral anticoagulants (NOACs) at preventing major neurological, cardiovascular or bleeding events in high-risk atrial fibrillation (AF) patients after 4 years, according to the PRAGUE-17 trial.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details